Viewing Study NCT06449820



Ignite Creation Date: 2024-06-16 @ 11:51 AM
Last Modification Date: 2024-10-26 @ 3:31 PM
Study NCT ID: NCT06449820
Status: RECRUITING
Last Update Posted: 2024-06-10
First Post: 2024-04-15

Brief Title: Janus Kinase Inhibitors for the Treatment of Acute Severe Ulcerative Colitis
Sponsor: Central Hospital Nancy France
Organization: Central Hospital Nancy France

Study Overview

Official Title: Janus Kinase Inhibitors for the Treatment of Acute Severe Ulcerative Colitis a Retrospective Cohort Study
Status: RECRUITING
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ATTRACT
Brief Summary: Ulcerative colitis UC is an incurable immune-mediated inflammatory disease of the large bowel that typically requires long term immunosuppressive drugs to induce and maintain remission Hospitalisation due to severe uncontrolled disease is a common occurrence and estimated to affect up to 25 of UC patients Janus kinase inhibitors JAKi have attracted considerable attention as potential candidates for treating hospitalised patients with severe UC and are increasingly used in this setting For tofacitinib there are accumulating data supporting their use as effective induction agents to prevent colectomy and reduce length of hospitalisation however these are limited to small case series and small cohort studies only There are no published data for the use of filgotinib and upadacitinib for treating severe inpatient colitis

The aim of this study is to develop a large retrospective cohort of JAKi-treated hospitalised UC patients to describe the safety and effectiveness of using JAKi in this setting
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None